163 related articles for article (PubMed ID: 23324306)
1. Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease.
Takada Y; Matsuo K
Keio J Med; 2012; 61(4):120-7. PubMed ID: 23324306
[TBL] [Abstract][Full Text] [Related]
2. Interstitial lung disease induced by gefitinib and toll-like receptor ligands is mediated by Fra-1.
Takada Y; Gresh L; Bozec A; Ikeda E; Kamiya K; Watanabe M; Kobayashi K; Asano K; Toyama Y; Wagner EF; Matsuo K
Oncogene; 2011 Sep; 30(36):3821-32. PubMed ID: 21460858
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells.
Koyama S; Omura T; Yonezawa A; Imai S; Nakagawa S; Nakagawa T; Yano I; Matsubara K
PLoS One; 2015; 10(8):e0136176. PubMed ID: 26288223
[TBL] [Abstract][Full Text] [Related]
4. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Tammaro KA; Baldwin PD; Lundberg AS
J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
6. Role of tyrosine kinase inhibitors in lung cancer.
Ansari J; Palmer DH; Rea DW; Hussain SA
Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
[TBL] [Abstract][Full Text] [Related]
7. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
8. Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
Wang KF; Chang CY; Chang SC; Liu YC; Yuan MK; Yang YH
J Chin Med Assoc; 2013 Mar; 76(3):173-5. PubMed ID: 23497972
[TBL] [Abstract][Full Text] [Related]
9. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
[TBL] [Abstract][Full Text] [Related]
10. EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis.
Hardie WD; Davidson C; Ikegami M; Leikauf GD; Le Cras TD; Prestridge A; Whitsett JA; Korfhagen TR
Am J Physiol Lung Cell Mol Physiol; 2008 Jun; 294(6):L1217-25. PubMed ID: 18424623
[TBL] [Abstract][Full Text] [Related]
11. Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class.
Haber DA; Settleman J
Cell Cycle; 2005 Aug; 4(8):1057-9. PubMed ID: 15970680
[TBL] [Abstract][Full Text] [Related]
12. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).
Siegel-Lakhai WS; Beijnen JH; Schellens JH
Oncologist; 2005 Sep; 10(8):579-89. PubMed ID: 16177282
[TBL] [Abstract][Full Text] [Related]
13. [Comparative evaluation of adverse reactions between gefitinib and erlotinib treatments in the same patients].
Ohashi Y; Suzuki K; Sakurai M; Shino M; Murakami H; Takahashi T; Yamamoto N
Gan To Kagaku Ryoho; 2009 Aug; 36(8):1327-31. PubMed ID: 19692772
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
15. Suppression of expression of heat shock protein 70 by gefitinib and its contribution to pulmonary fibrosis.
Namba T; Tanaka K; Hoshino T; Azuma A; Mizushima T
PLoS One; 2011; 6(11):e27296. PubMed ID: 22096546
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of gefitinib sensitivity with radioiodinated PHY based on EGFR expression.
Yoshimoto M; Hirata M; Kanai Y; Naka S; Nishii R; Kagawa S; Kawai K; Ohmomo Y
Biol Pharm Bull; 2014; 37(3):355-60. PubMed ID: 24583857
[TBL] [Abstract][Full Text] [Related]
17. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
Shi L; Tang J; Tong L; Liu Z
Lung Cancer; 2014 Feb; 83(2):231-9. PubMed ID: 24332320
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.
Furuyama K; Harada T; Iwama E; Shiraishi Y; Okamura K; Ijichi K; Fujii A; Ota K; Wang S; Li H; Takayama K; Giaccone G; Nakanishi Y
Cancer Sci; 2013 May; 104(5):584-9. PubMed ID: 23387505
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of quinoxalin-2(1H)-one derivatives as EGFR tyrosine kinase inhibitors.
Qin X; Han X; Hu L; Li Z; Geng Z; Wang Z; Zeng C; Xiao X
Anticancer Agents Med Chem; 2015; 15(2):267-73. PubMed ID: 25175686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
